^
4ms
A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=94, Recruiting, Zhejiang Doer Biologics Co., Ltd. | Trial primary completion date: Jun 2024 --> Jun 2025
Trial primary completion date • Metastases
|
CLDN18 (Claudin 18)
|
DR30303
10ms
A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=94, Recruiting, Zhejiang Doer Biologics Co., Ltd. | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Sep 2023 --> Jun 2024
Trial completion date • Trial primary completion date • Metastases
|
CLDN18 (Claudin 18)
|
CLDN18.2 positive
|
DR30303
almost2years
New P1 trial • Metastases
|
CLDN18 (Claudin 18)
|
CLDN18.2 positive
|
DR30303